Julphar, the Ras Al Khaimah based pharmaceutical group formerly known as Gulf Pharmaceutical Industries, has appointed Khaled Khalil as its chief commercial officer. The company disclosed the appointment on 17 August 2026 in a same day notice, with the move taking effect immediately.
Julphar is listed on the Abu Dhabi Securities Exchange, and the disclosure identified the incoming executive in full as Khaled Tawfik Mohamed Khalil. The company lists him on its executive team page under the shorter form Khaled Khalil, which is the spelling Julphar itself uses, although some wire coverage rendered his first name as Khalid.
The commercial post had changed hands earlier in the year. Trade coverage in April 2026 reported that the previous chief commercial officer was stepping down, and the company has now filled the seat permanently, completing an orderly transition at the top of its commercial organisation.
Khalil arrives with more than 30 years of executive commercial leadership experience across the pharmaceutical and medical nutrition sectors, with responsibility spanning the GCC, the wider Middle East, Africa, Turkey and Pakistan. Immediately before joining Julphar he was general manager at Pharco Pharmaceuticals. He spent more than a decade at Abbott Nutrition as regional director, and earlier held leadership roles at GlaxoSmithKline, Mepha and Eli Lilly. He holds a Bachelor of Pharmaceutical Sciences from Cairo University and has completed executive leadership programmes at international institutions.
According to Julphar, his career has centred on multi market profit and loss ownership, business transformation, market expansion and the building of commercial teams. In the new role he takes charge of the group's commercial leadership function, covering the sales, marketing and market access engine that carries Julphar products into the home market and export territories.
The commercial brief matters because Julphar's recent performance has been driven more by margin than by volume. In half year results published on 13 August 2026, the company reported revenue from continuing operations of AED 573.7 million, up 4.7 per cent year on year, gross profit up 18.3 per cent at AED 261.2 million, and EBITDA up 84.7 per cent at AED 86.8 million. Converting that restored profitability into faster top line growth is squarely a commercial task, and it is the task the new chief commercial officer inherits.
The appointment came alongside a second commercial hire. Faisal Al Tlasi was named general manager for Julphar Saudi Arabia, giving the group dedicated country leadership in that market. Together the two moves deepen the senior commercial bench at a point when regional manufacturers are competing harder for tender business and for share in retail pharmacy.
Julphar is an Emirati pharmaceutical manufacturer headquartered in Ras Al Khaimah. It employs more than 5,000 people, distributes medicines internationally, and its shares trade in Abu Dhabi. The group sells across the Gulf and into wider Middle East and African markets, where competition from regional generic manufacturers and from imported branded medicines has intensified, making commercial execution a central determinant of its results.
